Investors Eye Lead Role in Zoetis Securities Fraud Class Action

Investors who incurred financial losses holding Zoetis Inc. stock between January 2025 and May 2026 are being sought to serve as lead plaintiffs in a class action lawsuit. The filing, spearheaded by Glancy Prongay Wolke & Rotter LLP, targets the company over alleged failures to disclose critical market and safety setbacks.

The litigation centers on claims that the animal health giant misled shareholders regarding the performance and safety profiles of its core product lineup. The complaint alleges that management suppressed information about weakening adoption rates for Librela, the company's canine pain treatment, following FDA warnings that linked the drug to serious neurological complications. Simultaneously, the lawsuit contends that Zoetis failed to acknowledge significant market share erosion for its parasiticide, Simparica Trio, and its dermatology staples, Apoquel and Cytopoint, both of which faced pressure from more affordable or recently launched competitors.

Those seeking to participate in the litigation must file their requests by the July 27, 2026 deadline. While investors may choose to retain their own counsel, the firm is currently coordinating with those impacted to consolidate claims against the company. The legal action asserts that the company’s public statements throughout the specified period lacked a reasonable basis, leaving investors vulnerable to losses as the underlying business conditions deteriorated.